NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that the Company will be participating in the following investor conferences in January: January 12-13, 2026: ICR Conference in Orlando, FL. The Company will host meetings with investors throughout the event.January 14, 2026: CJS Securities 26th Annual New Ideas for the New Year. The Company will be participating in a vir ...

Core Insights - Weight Watchers has launched the Med+ program, integrating Novo Nordisk's newly FDA-approved oral formulation of Wegovy, enhancing access to GLP-1 treatments and reinforcing its leadership in comprehensive weight management care [1][4] Group 1: Integrated Care Model - Weight Watchers is recognized as a NovoCare provider, delivering FDA-approved GLP-1 medications alongside expert clinical care through its Med+ and GLP-1 Success Program [2] - The integrated care model combines access to board-certified physicians, evidence-based behavioral science, coaching, community support, and digital tools, leading to better real-world outcomes [2][5] - Members engaging with the GLP-1 Success Program lost 61.3% more body weight at one month and 29.1% more at twelve months compared to those not engaged in the program [4] Group 2: Leadership and Innovation - CEO Tara Comonte emphasized that the next era of weight health focuses on helping individuals succeed with medication, highlighting the importance of support in achieving results [3] - The introduction of the Wegovy pill offers a once-daily option, appealing to individuals hesitant about injectable therapies, with access starting at $149 per month [4] - Weight Watchers aims to expand access to GLP-1 treatments while ensuring patients receive necessary support beyond prescriptions [4][5] Group 3: Company Background - Weight Watchers has over 60 years of experience in science-backed weight management, being the most studied commercial weight management program globally [6][7] - The company provides a holistic approach that includes clinical interventions and access to GLP-1 medications when appropriate, supported by a global network of coaches and community [7] - Weight Watchers offers solutions directly to members and through its platform for employers, health plans, and payers, focusing on personalized support [7]

Group 1 - U.S. stocks experienced a decline, with the Dow Jones index dropping over 100 points on Tuesday [1] - Cementos Pacasmayo SAA – ADR shares surged 47.4% to $10.30 following Holcim's agreement to acquire 50.01% of its owner, Inversiones Aspi. S.A. [1] Group 2 - Rezolve AI PLC reported preliminary December revenue results, leading to a 23.7% increase in its stock price to $2.87 [2] - Emerald Holding Inc announced a review of potential strategic options, resulting in a 17% rise in its stock price to $4.14 [2] - NovaBay Pharmaceuticals Inc's stock increased by 16.2% to $3.15 [2] - Tilray Brands Inc saw a 15% surge in its stock price to $12.57 [2] - Clearpoint Neuro Inc's stock jumped 14.2% to $14.14 [2] - Fermi Inc gained 11.4%, reaching $9.57 [2] - Sezzle Inc authorized a $100 million stock buyback, leading to a 9.6% increase in its stock price to $72.49 [2] - WW International Inc launched a new platform for the GLP-1 era, resulting in a 7.8% gain to $26.19 [2] - Circle Internet Group Inc rose 7.7% to $81.24 [2] - Lemonade Inc's stock surged 7.4% to $80.59 [2] - Netskope Inc gained 6.9%, reaching $20.37 [2] - Ascentage Pharma Group International's stock rose 6% to $29.26 [2] - RH's stock increased by 5.5% to $172.60, with Barclays analyst maintaining an Overweight rating and lowering the price target from $385 to $283 [2] - Affirm Holdings Inc gained 4.4%, reaching $68.56 [2]

Core Insights - WW International, Inc. (Weight Watchers) has launched a new integrated experience that combines GLP-1 prescribing, personalized nutrition, behavioral support, coaching, and community within a redesigned app [1][2] - The new offering aims to provide coordinated, evidence-based support to help members achieve and sustain superior weight management results [1][2] GLP-1 Program and Support - Weight Watchers Med+ is a dedicated GLP-1 medical program that connects members with board-certified physicians who specialize in obesity and metabolic health, providing prescriptions and ongoing medical guidance [3] - The GLP-1 Success program offers personalized nutrition guidance, tools for tracking weight loss and medication doses, and strategies for managing side effects, enhancing the effectiveness of GLP-1 medications [4][5] - Over 70% of Weight Watchers Med+ members on the GLP-1 Success Program report that it helps minimize side effects from weight loss medications [4] Digital Experience and Tools - The new digital experience includes the Weight Health Score, an evidence-based metric that helps members track their daily habits and progress [6][7] - An AI-powered body scanner provides insights into changes in fat and muscle mass, which is particularly beneficial for members using GLP-1 medications [7][8] - Members will have access to exclusive fitness content and can choose from different modes that adjust support levels based on their weight management journey [9][10] Community and Coaching - Weight Watchers emphasizes the importance of community support, offering small, coach-led groups focused on various topics, including GLP-1 use and nutrition [12][13] - The company is expanding its virtual experience and curated programming to enhance community support for members [12] Brand Evolution - Weight Watchers is introducing a refreshed brand identity that reflects its evolution and commitment to integrated, evidence-based weight management solutions [14][15] - The new branding aims to convey stability, trust, and a focus on sustainable health outcomes, aligning with the company's mission to support members in their weight management journeys [15][16] Availability - The new integrated experience will be rolled out globally starting December 26, with the Weight Watchers app available on both iOS and Android platforms [16]

Core Insights - Weight Watchers has launched a new integrated experience that combines GLP-1 prescriptions with personalized nutrition, coaching, and community support to enhance weight management and long-term health outcomes [1][15][18] Group 1: New Offerings - The new Weight Watchers Med+ program provides members access to board-certified physicians who specialize in obesity and metabolic health, offering GLP-1 prescriptions and ongoing medical guidance [3] - The GLP-1 Success program includes personalized nutrition guidance, tools for tracking weight loss and medication doses, and strategies for managing side effects, aiming to improve outcomes beyond medication alone [4][5] - Members using GLP-1s in conjunction with Weight Watchers report greater weight loss and higher satisfaction, with 90% expressing interest in community support programs [2] Group 2: Digital Experience Enhancements - A redesigned digital platform features the Weight Health Score, an evidence-based metric that helps members track their daily habits and progress [7] - An AI-powered body scanner provides insights into changes in fat and muscle mass, which is particularly beneficial for members using GLP-1 medications [7] - The app will include exclusive fitness content and flexible modes that adjust support levels based on members' weight management phases [6][8] Group 3: Community and Support - Weight Watchers emphasizes the importance of community support, offering small, coach-led groups focused on various topics, including GLP-1 use and nutrition [10][11] - The company is expanding its virtual experience to enhance member connection and support, building on its 62-year legacy of community engagement [10][12] Group 4: Brand Evolution - Weight Watchers is introducing a refreshed brand identity that reflects its integrated, evidence-based approach to weight management [12][16] - The new branding aims to convey stability and trust, aligning with the company's commitment to sustainable health outcomes [16][17]

Core Insights - WW International, Inc. has emerged from bankruptcy earlier this year, presenting a potential investment opportunity in their growing Clinical Business [1] Company Overview - WW International, Inc. is focusing on expanding its Clinical Business, which may attract investors looking for growth in this sector [1]

Core Insights - WW International has emerged from bankruptcy earlier this year, presenting a potential investment opportunity in their growing Clinical Business [1] Company Overview - WW International is focusing on expanding its Clinical Business, which is seen as a key growth area following its bankruptcy exit [1]

Company Overview - WW International Inc. has filed for bankruptcy earlier this year and is struggling to maintain relevance after relisting on the Nasdaq [1][5] - The company was once a dominant player in the weight-loss industry, heavily endorsed by Oprah Winfrey, who also served on its board [5] Industry Challenges - The rise of GLP-1 weight-loss drugs from companies like Novo Nordisk and Eli Lilly has significantly impacted traditional weight-loss programs, leading to a decline in WW International's consumer base [2][5] - The company is currently in a turnaround phase, introducing new programs such as menopause management to diversify its offerings beyond weight loss [6] Financial Performance - WW International's stock has decreased by 8.56% since relisting on the Nasdaq [5] - The company's Growth score in Benzinga's Edge Rankings has dropped dramatically from 68.77 to 13.22 within a week, following a 10% year-over-year decline in revenue and missing analyst estimates for both top and bottom lines [6]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - WeightWatchers reported third-quarter 2025 financial results that exceeded revenue and adjusted profit expectations, leading to a 10.6% increase in shares [1][2] - Total revenue decreased by 10.8% year-over-year to $172.1 million, but still surpassed analyst estimates [2] - The company experienced a GAAP loss of $5.76 per share, which was significantly worse than Wall Street's expectations [2] - WeightWatchers achieved an adjusted EBITDA of $42.78 million, exceeding forecasts, and management raised its full-year revenue guidance and provided an optimistic outlook for adjusted EBITDA [2] Market Reaction - WeightWatchers shares are highly volatile, with 27 moves greater than 5% in the past year, indicating significant market impact from recent news [4] - The broader market showed caution, with the tech-heavy Nasdaq falling approximately 1.4%, reflecting profit-taking behavior among investors [5] - Leadership at Goldman Sachs and Morgan Stanley suggested a potential correction in equity markets over the next couple of years, viewing it as a healthy feature of a long-term bull market [6] Performance Metrics - WeightWatchers shares have increased by 41.5% since the beginning of the year, currently trading at $38.21, which is 14.9% below its 52-week high of $44.89 [7] - An investment of $1,000 in WeightWatchers shares at the IPO in June 2025 would now be valued at $1,415 [7]